Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATA520 |
Synonyms | |
Therapy Description |
ATA520 (WT1-CTL) is a preparation of cytotoxic T lymphocytes specifically targeting WT1, which may induce cytotoxic immune response against WT1-expressing tumor cells (Blood 2015 126(23):98). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATA520 | WT1-CTL | ATA520 (WT1-CTL) is a preparation of cytotoxic T lymphocytes specifically targeting WT1, which may induce cytotoxic immune response against WT1-expressing tumor cells (Blood 2015 126(23):98). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00620633 | Phase I | ATA520 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Completed | USA | 0 |